Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
Myelodysplastic Syndrome
About this trial
This is an interventional treatment trial for Myelodysplastic Syndrome focused on measuring Myelodysplastic Syndrome
Eligibility Criteria
Inclusion Criteria: Histologic diagnosis of high-risk MDS (IPSS int-2). No prior cytotoxic therapy for MDS or AML (patients may have received prior therapy with hematopoietic growth factors, immunomodulatory agents or 5-azacitidine). Exclusion Criteria: Pregnant or lactating women. Absolute QT interval >460 msec in the presence of serum potassium and magnesium values within the normal range. Concurrent treatment with maintenance therapy, cytotoxic chemotherapy, radiation, or investigational agents. Uncontrolled or severe cardiovascular or pulmonary disease.
Sites / Locations
- Weill Medcial College of Cornell University
Arms of the Study
Arm 1
Experimental
All Patients
Arsenic trioxide [TrisenoxTM Injection], 0.25mg/kg/dose administered intravenously over 1 to 4 hours